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TransplantatABSTRACT
Background. Granulocyte and monocyte adsorptive apheresis (GMAA) is widely used as
a treatment for active ulcerative colitis (UC) in Japan. Much attention has been paid to the
possibility of GMAA for the treatment and control of cytomegalovirus (CMV) reactivation
in patients with refractory UC and concomitant CMV infection. In this study, the effects of
the combination of GMAA and antiviral therapy were examined in renal transplant
recipients with concomitant CMV infection.
Methods. Combination therapy of GMAA and antiviral drugs was performed 9 times in 7
renal transplant recipients with concomitant CMV infection. Four of the cases were pos-
itive for CMV-IgG, and 3 were negative. The clinical presentation of CMV infection was
viremia in 6 cases and disease (CMV retinitis) in 1 case. CMV infection was diagnosed
by using an antigenemia assay (C7-HRP). GMAA session was performed once, and the
duration of the session was 120 min. Immediately after the GMAA session, ganciclovir
was administered at 5 mg/kg/body weight. CMV infection was monitored based on C7-
HRP and CMV-DNA in the peripheral blood samples.
Results. All cases became negative for C7-HRP and CMV-DNA within 21 days (median,
14 days; range, 3e21 days) and 17 days (median, 6 days; range, 3e17 days), respectively,
after starting the combination therapy. No side effects of GMAA were observed.
Conclusions. This case series found that GMAA in combination with antiviral drugs may
shorten the duration of treatment against CMV infection in renal transplant recipients.
Further studies in a larger number of patients are required to conﬁrm these results.This research was supported by grants from the Osaka City
University Medical Research Foundation.
*Address correspondence to Toshihide Naganuma, MD, Osaka
City University Graduate School of Medicine, 1-4-3 Asahi-machi,
Abeno-ku, Osaka 545-8585, Japan. E-mail: spxd48k9@aria.ocn.
ne.jpRECENT ADVANCEMENTS IN IMMUNOSUP-PRESSIVE therapies have improved the clinical
outcome of patients with renal transplantation, but cyto-
megalovirus (CMV) infection is still a major clinical issue.
CMV infection in renal transplant recipients is a signiﬁcant
cause of postoperative death and is associated with acute
rejection and chronic or mild allograft nephropathy [1e5].
Therefore, management of CMV infection in patients with
renal transplantation is critically important. The mechanism
of CMV reactivation is generally believed to involve local
expression of a wide variety of proinﬂammatory cytokinesAuthors. Published by Elsevier Inc. This is an open
le under the CC BY-NC-ND license (http://
mons.org/licenses/by-nc-nd/4.0/).
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ion Proceedings, 48, 929e932 (2016)that play a crucial role in recruiting immune cells, including
monocytes, to inﬂammatory organs [6e9]. Proinﬂammatory
cytokines such as interferon gamma and tumor necrosis
factor a promote reactivation of CMV in monocytes and0041-1345/16
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930 NAGANUMA, TAKEMOTO, IWAI ET ALdendritic cells. Stimulated by release of these cytokines and
chemokines from inﬂammatory organs, latently infected
circulating monocytes and dendritic cells likely migrate to
these sites and differentiate into permissive cells, supporting
active replication of CMV.
Granulocyte and monocyte adsorptive apheresis (GMAA)
is a widely used treatment for inﬂammatory bowel disease in
Japan [10]. GMAA may reduce proinﬂammatory cytokines
(tumor necrosis factor a and interleukin 1b) and decrease the
number of monocytes positive for CD14, CD16, and DR
subsets [11e13]. GMAA is effective for patients with ulcer-
ative colitis (UC) and concomitant CMV under immuno-
suppressive therapy because it can reduce proinﬂammatory
cytokines reactivating CMV and remove CMV-permissive
cells without excessive immunosuppression [14,15]. In the
present study, the effects of a combination of GMAA and
antiviral therapy were examined in renal transplant recipients
with concomitant CMV infection.
PATIENTS AND METHODS
Study Participants
Combination therapy of GMAA and antiviral drugs was performed
in 7 renal transplant recipients (median age, 56 years; range, 40e69
years) with concomitant CMV infection. A second course of com-
bination therapy was performed in 2 patients (cases 4 and 6) due to
CMV reactivation, and thus combination therapy was administered
a total of 9 times. The baseline characteristics of all cases are shown
in Table 1. Four cases were positive for CMV-IgG, and 3 were
negative. The clinical presentation of CMV infection was viremia in
6 cases and disease (CMV retinitis) in 1 case (case 6). Cases 5 and 7
had received preventive administration of valganciclovir.
All subjects gave written informed consent for participation in
the study. The protocol was approved by the ethics committee of
Osaka City University Graduate School of Medicine (no. 2236).
Diagnosis of CMV Infection
Cases diagnosed as CMV antigenemia by using C7-HRP (SRL Inc.,
Tokyo, Japan) were deﬁned as positive for CMV infection. GMAA
in combination with antiviral therapy was initiated for recipients
with >5 CMV antigen-positive cells/50,000 leukocytes according to
C7-HRP. CMV infection was mainly monitored by using C7-HRP,Table 1. Baseline Charac
Case Age (y) Sex
Living/Deceased
Donor
Acute
Rejection
Period After
Transplant CMV-
1 40 Male Living þ 8 mo Dþ/R
2 41 Female Deceased e 1 mo Dþ/R
3 60 Male Deceased e 1 mo Dþ/R
4 56 Male Incompatible living e 3 wk Dþ/R
5* 58 Male Incompatible living þ 5 mo Dþ/R
6 69 Male Living e 118 mo Dþ/R
7* 44 Male Deceased e 1 mo Dþ/R
4† 56 Male Incompatible living e 8 mo Dþ/R
6† 70 Male Living e 124 mo Dþ/R
Abbreviations: CMV, cytomegalovirus; PCR, polymerase chain reaction; pp65, 65
positive; Dþ/R, Donor seropositive/Recipient seronegative.
*Administration of preventive valganciclovir.
†Underwent a second course of GMAA.but CMV-DNA copy number was also measured by using quanti-
tative real-time polymerase chain reaction (PCR).
CMV Antigenemia and Quantitative Real-Time PCR
The antigenemia assay was performed by using a monoclonal
antibody (C7-HRP) against a CMV structural protein of the 65-kDa
lower matrix phosphoprotein (pp65) [16]. Peripheral blood was
drawn at the same time as for C7-HRP and stored at 4C. The
CMV-DNA copy number was determined by using quantitative
real-time PCR [14,15,17].
Treatment Protocol
The GMAA session was performed once by using Adacolumn
(JIMRO Co, Ltd, Gunma, Japan). Vascular access was via a veni-
puncture in the antecubital vein of 1 arm and from the column
outﬂow, and blood return to the patient was via a venipuncture
in the contralateral arm. The duration of the GMAA session
was 120 min at 30 mL/min. An optimum dose of sodium heparin
(2000 U/session) was administered during GMAA as an anticoag-
ulant agent. Immediately after the GMAA session, regular treat-
ment was performed using ganciclovir at 5 mg/kg/body weight.
Virologic Follow-up of CMV
Detection of C7-HRP and CMV-DNA in peripheral blood samples
by using quantitative real-time PCR was performed before and after
GMAA and on days 3 and 7 post-GMAA. Thereafter, detection
of C7-HRP and CMV-DNA was conducted every other week.
There were differences in measurement dates for some cases due to
holidays.
RESULTS
All cases (Table 2) became negative for C7-HRP and CMV-
DNA within 21 days (median, 14 days; range, 3e21 days)
and 17 days (median, 6 days; range, 3e17 days), respectively,
after starting the combination therapy. Among the CMV
viremia cases, CMV-IgGepositive cases became negative
for C7-HRP and CMV-DNA within 14 days (range, 3e14
days) and 10 days (range, 3e10 days), whereas CMV-IgGe
negative cases became negative for C7-HRP and CMV-
DNA within 18 days (range, 10e18 days) and 10 days
(range, 3e10 days). CMV retinitis cases became negative forteristics of All Cases
IgG
Clinical Presentation
of CMV Infection
Pre-GMAA Level of
C7-HRP (pp65-Positive
Cells/50,000 Leukocytes)
Pre-GMAA Level in
Quantitative Real-Time
PCR (Copies/mg DNA)
þ Viremia 89 30
þ Viremia 37 10
 Viremia 182 10
þ Viremia 7 <10
 Viremia 17 <10
þ Disease (retinitis) 108 190
 Viremia 307 <10
þ Viremia 127 2300
þ Disease (retinitis) 314 720
-kDa lower matrix phosphoprotein; Dþ/Rþ, donor seropositive/Recipient sero-
Table 2. Outcomes Based on CMV-Negative Periods
Case CMV-AgeNegative Period (d) CMV-DNAeNegative Period (d)
1 3 3
2 14 3
3 18 3
4 3 3
5* 10 10
6 21 7
7* 17 6
4† 10 10
6† 21 17
Abbreviations: CMV, cytomegalovirus; CMV-Ag, CMV-antigenemia.
*Administration of preventive valganciclovir.
†Underwent a second course of granulocyte and monocyte adsorptive
apheresis.
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7e17 days). No side effects of GMAA were observed.DISCUSSION
In this study, we examined 7 renal transplant recipients with
concomitant CMV infection who were treated with a com-
bination of GMAA and antiviral therapy. This case series
suggests that GMAA in combination with antiviral drugs
could shorten the duration of treatment for CMV infection
in renal transplant recipients.
Both an allogeneic response and immunosuppression in
renal transplant recipients can induce CMV reactivation
[1e5]. Although antiviral drugs such as ganciclovir, valgan-
ciclovir, foscarnet, and cidofovir are generally used, long-
term use of these drugs may be accompanied by side
effects such as myelosuppression and the development of
antiviral drugeresistant strains [18e21]. GMAA is believed
to remove monocytes/macrophages, which are reservoirs of
CMV, from the peripheral blood but not to affect lympho-
cytes, which play an important role in inhibiting CMV
reactivation [11e13]. In fact, GMAA was found to be
effective for patients with UC and concomitant CMV
infection under immunosuppressive therapy [14,15]. Taken
together, these ﬁndings suggest that GMAA in combination
with antiviral drugs might be a rational therapeutic strategy
for renal transplant recipients infected with CMV.
In the present study, all cases became negative for
C7-HRP and CMV-DNA within 21 days (median, 14 days;
range, 3e21 days) and 17 days (median, 6 days; range, 3e17
days), respectively, after the start of combination therapy.
Among the CMV viremia cases, it was of note that CMV-
IgGepositive cases became negative for C7-HRP and CMV-
DNA within 14 and 10 days, whereas CMV-IgGenegative
cases became negative for C7-HRP and CMV-DNA within
18 and 10 days. CMV retinitis cases became negative for
C7-HRP and CMV-DNA within 21 and 18 days. Compared
with the median therapeutic duration of CMV viremia
of >3 weeks previously found in renal transplantation re-
cipients who were seropositive for CMV [22e24], our cases
suggest that GMAA in combination with antiviral therapy
can shorten the duration of CMV infection.In 5 cases, the patients became negative for C7-HRP after
CMV-DNA was not detected in peripheral blood samples.
This result is consistent with previous reports showing a
time difference between the disappearance of pp65 antigen
and that of CMV-DNA from peripheral blood samples
during anti-CMV treatment [25]. These ﬁndings indicate
that viral reactivation can be suppressed at an early stage
after starting the combination therapy.CONCLUSIONS
This report is the ﬁrst to show the effects of GMAA on renal
transplant recipients infected with CMV to the best of our
knowledge. Our results suggest that a combination ofGMAA
therapy with antiviral drugs can shorten the therapeutic
duration of CMV infection in renal transplant recipients.
Moreover, our patients did not experience any adverse ef-
fects related to GMAA therapy. Further studies in a larger
number of patients are required to conﬁrm these results.REFERENCES
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